Topic
Geroprotector
About: Geroprotector is a research topic. Over the lifetime, 67 publications have been published within this topic receiving 2727 citations. The topic is also known as: Anti-aging substances.
Papers published on a yearly basis
Papers
TL;DR: It is shown that long-term treatment with metformin starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic.
Abstract: Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol levels without a decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein kinase activity and increases antioxidant protection, resulting in reductions in both oxidative damage accumulation and chronic inflammation. Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in agreement with current epidemiological data and raise the possibility of metformin-based interventions to promote healthy aging.
1,311 citations
TL;DR: Metformin, which has demonstrated protective effects against several age-related diseases in humans, will be tested in the TAME (Targeting Aging with Metformin) trial, as the initial step in the development of increasingly effective next-generation drugs.
891 citations
TL;DR: Melatonin may be used for the prevention of premature aging and carcinogenesis and increased the expression of some mitochondrial genes, which agrees with its ability to inhibit free radical processes.
263 citations
TL;DR: The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies and its role as a potential geroprotector is discussed.
Abstract: Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.
148 citations
TL;DR: This work screened for aging-preventive compounds, known as geroprotectors, employing the power of transcriptomics to predict biological age and was able to identify a class that acts by improving protein homeostasis, testing the top candidates in C. elegans.
84 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2021 | 5 |
| 2020 | 7 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 6 |